Gabrielle Capaldo

1 week ago | healio.com | Gabrielle Capaldo

Key takeaways: HS unroofing for certain anatomic locations increased by as much as 116%. Dermatologists must help guide patients toward better coverage and education on HS treatment. The cost to treat hidradenitis suppurativa has increased by as much as 116% after adjustment for inflation, causing a historically disadvantaged group of patients to pay higher out-of-pocket costs, according to a study.

2 weeks ago | healio.com | Gabrielle Capaldo

Key takeaways: Roflumilast foam 0.3% is a formulation that can treat psoriasis-affected skin in hair-bearing areas. It also gives patients a nonsteroidal option that can be used long term. The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body for adults and children aged 12 years and older, according to an industry press release.

2 weeks ago | healio.com | Gabrielle Capaldo

Key takeaways: Itch was long misunderstood. Now, it is a rapidly growing field of research. Experts discuss the science behind itch and how a patient-centric approach propelled the field to where it is today. The story of chronic itch and its impact on quality of life is one dermatologists have heard often. Until recently, treatment options were limited. Such was the case for Denise Thomma, an elementary school librarian and patient of Shawn G. Kwatra, MD, the Joseph W.

2 weeks ago | healio.com | Gabrielle Capaldo

Key takeaways: Some patients had residual inflammation 1 year after biologic therapy or stable biologic maintenance treatment. BMI and female sex were associated with having residual inflammation. Residual inflammation persisted among patients with psoriasis despite optimal disease response to biologic therapies, putting them at risk for broader health conditions, according to a study.

3 weeks ago | healio.com | Gabrielle Capaldo

Key takeaways: By week 8, patients treated with roflumilast saw higher efficacy outcomes than those treated with the vehicle. Nearly all the treatment-emergent adverse events were mild to moderate in severity. Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body psoriasis, according to a study published in JAMA Dermatology.